nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimozide—CYP1A2—Imiquimod—skin cancer	0.0866	0.126	CbGbCtD
Pimozide—CYP2C19—Vismodegib—skin cancer	0.065	0.0944	CbGbCtD
Pimozide—CYP2E1—Dacarbazine—skin cancer	0.0629	0.0913	CbGbCtD
Pimozide—ABCB1—Vismodegib—skin cancer	0.0525	0.0762	CbGbCtD
Pimozide—CYP1A2—Vemurafenib—skin cancer	0.0474	0.0689	CbGbCtD
Pimozide—CYP3A4—Imiquimod—skin cancer	0.0454	0.0659	CbGbCtD
Pimozide—CYP3A4—Temozolomide—skin cancer	0.0454	0.0659	CbGbCtD
Pimozide—CYP2D6—Vemurafenib—skin cancer	0.0391	0.0568	CbGbCtD
Pimozide—CYP1A2—Dacarbazine—skin cancer	0.0364	0.0528	CbGbCtD
Pimozide—CYP3A4—Vismodegib—skin cancer	0.0314	0.0457	CbGbCtD
Pimozide—CYP3A7—Docetaxel—skin cancer	0.0292	0.0423	CbGbCtD
Pimozide—CYP3A7-CYP3A51P—Docetaxel—skin cancer	0.0292	0.0423	CbGbCtD
Pimozide—ABCB1—Dactinomycin—skin cancer	0.0276	0.04	CbGbCtD
Pimozide—CYP3A4—Vemurafenib—skin cancer	0.0249	0.0361	CbGbCtD
Pimozide—CYP3A5—Docetaxel—skin cancer	0.0219	0.0318	CbGbCtD
Pimozide—CYP1A2—Fluorouracil—skin cancer	0.0213	0.031	CbGbCtD
Pimozide—ABCB1—Docetaxel—skin cancer	0.0142	0.0207	CbGbCtD
Pimozide—CYP3A4—Docetaxel—skin cancer	0.00853	0.0124	CbGbCtD
Pimozide—HRH1—nose—skin cancer	0.00537	0.0697	CbGeAlD
Pimozide—Amenorrhoea—Vismodegib—skin cancer	0.00394	0.025	CcSEcCtD
Pimozide—Electrocardiogram change—Fluorouracil—skin cancer	0.00352	0.0223	CcSEcCtD
Pimozide—CALM2—ear—skin cancer	0.00337	0.0437	CbGeAlD
Pimozide—CALM1—ear—skin cancer	0.00335	0.0435	CbGeAlD
Pimozide—Electrocardiogram QT prolonged—Vemurafenib—skin cancer	0.00333	0.0211	CcSEcCtD
Pimozide—Periorbital oedema—Bleomycin—skin cancer	0.00328	0.0208	CcSEcCtD
Pimozide—Abnormal behaviour—Temozolomide—skin cancer	0.00293	0.0186	CcSEcCtD
Pimozide—OPRM1—nerve—skin cancer	0.00292	0.0379	CbGeAlD
Pimozide—Hyponatraemia—Vismodegib—skin cancer	0.00252	0.016	CcSEcCtD
Pimozide—Skin irritation—Fluorouracil—skin cancer	0.00233	0.0148	CcSEcCtD
Pimozide—Breast disorder—Vismodegib—skin cancer	0.00227	0.0144	CcSEcCtD
Pimozide—Parkinsonism—Fluorouracil—skin cancer	0.00221	0.0141	CcSEcCtD
Pimozide—Faecal incontinence—Temozolomide—skin cancer	0.00216	0.0137	CcSEcCtD
Pimozide—CALM2—nerve—skin cancer	0.00212	0.0275	CbGeAlD
Pimozide—HTR2A—hindlimb—skin cancer	0.00211	0.0274	CbGeAlD
Pimozide—CALM1—nerve—skin cancer	0.00211	0.0274	CbGeAlD
Pimozide—Weight decreased—Vismodegib—skin cancer	0.00196	0.0125	CcSEcCtD
Pimozide—DRD2—nerve—skin cancer	0.00195	0.0253	CbGeAlD
Pimozide—HTR2A—appendage—skin cancer	0.00181	0.0235	CbGeAlD
Pimozide—CALM2—endothelium—skin cancer	0.0018	0.0234	CbGeAlD
Pimozide—CALM1—endothelium—skin cancer	0.0018	0.0233	CbGeAlD
Pimozide—CALM2—hair follicle—skin cancer	0.00177	0.023	CbGeAlD
Pimozide—Connective tissue disorder—Vismodegib—skin cancer	0.00171	0.0108	CcSEcCtD
Pimozide—CALM2—blood vessel—skin cancer	0.00166	0.0216	CbGeAlD
Pimozide—CALM1—blood vessel—skin cancer	0.00166	0.0215	CbGeAlD
Pimozide—CACNA1G—head—skin cancer	0.00153	0.0199	CbGeAlD
Pimozide—CALM3—nipple—skin cancer	0.00153	0.0199	CbGeAlD
Pimozide—Muscle spasms—Vismodegib—skin cancer	0.00145	0.00923	CcSEcCtD
Pimozide—Extrapyramidal disorder—Temozolomide—skin cancer	0.00145	0.00921	CcSEcCtD
Pimozide—Eosinophilia—Vemurafenib—skin cancer	0.00133	0.00843	CcSEcCtD
Pimozide—Endocrine disorder—Temozolomide—skin cancer	0.00132	0.00836	CcSEcCtD
Pimozide—Myalgia—Vismodegib—skin cancer	0.00129	0.00817	CcSEcCtD
Pimozide—HTR2A—nerve—skin cancer	0.00128	0.0167	CbGeAlD
Pimozide—Unspecified disorder of skin and subcutaneous tissue—Vismodegib—skin cancer	0.00128	0.00811	CcSEcCtD
Pimozide—Speech disorder—Temozolomide—skin cancer	0.00127	0.00806	CcSEcCtD
Pimozide—Urinary retention—Imiquimod—skin cancer	0.00126	0.00798	CcSEcCtD
Pimozide—Amenorrhoea—Temozolomide—skin cancer	0.00124	0.00789	CcSEcCtD
Pimozide—Weight decreased—Vemurafenib—skin cancer	0.00121	0.0077	CcSEcCtD
Pimozide—Nervous system disorder—Vismodegib—skin cancer	0.00121	0.00768	CcSEcCtD
Pimozide—CALM2—nipple—skin cancer	0.0012	0.0156	CbGeAlD
Pimozide—Skin disorder—Vismodegib—skin cancer	0.0012	0.00761	CcSEcCtD
Pimozide—CALM1—nipple—skin cancer	0.0012	0.0156	CbGeAlD
Pimozide—Breast disorder—Imiquimod—skin cancer	0.0012	0.00759	CcSEcCtD
Pimozide—CALM2—neck—skin cancer	0.00119	0.0155	CbGeAlD
Pimozide—CALM1—neck—skin cancer	0.00118	0.0154	CbGeAlD
Pimozide—Speech disorder—Fluorouracil—skin cancer	0.00117	0.00743	CcSEcCtD
Pimozide—OPRK1—female reproductive system—skin cancer	0.00117	0.0151	CbGeAlD
Pimozide—Aplastic anaemia—Dactinomycin—skin cancer	0.00113	0.0072	CcSEcCtD
Pimozide—Musculoskeletal discomfort—Vismodegib—skin cancer	0.00112	0.00714	CcSEcCtD
Pimozide—HTR2A—endothelium—skin cancer	0.00109	0.0142	CbGeAlD
Pimozide—DRD3—head—skin cancer	0.00109	0.0142	CbGeAlD
Pimozide—KCNH2—nipple—skin cancer	0.00109	0.0142	CbGeAlD
Pimozide—Pancytopenia—Imiquimod—skin cancer	0.00109	0.00689	CcSEcCtD
Pimozide—Decreased appetite—Vismodegib—skin cancer	0.00107	0.00681	CcSEcCtD
Pimozide—Gastrointestinal disorder—Vismodegib—skin cancer	0.00107	0.00676	CcSEcCtD
Pimozide—Constipation—Vismodegib—skin cancer	0.00106	0.0067	CcSEcCtD
Pimozide—Connective tissue disorder—Vemurafenib—skin cancer	0.00105	0.00669	CcSEcCtD
Pimozide—Erectile dysfunction—Imiquimod—skin cancer	0.00105	0.00668	CcSEcCtD
Pimozide—HTR6—head—skin cancer	0.00105	0.0137	CbGeAlD
Pimozide—Aplastic anaemia—Temozolomide—skin cancer	0.00103	0.00651	CcSEcCtD
Pimozide—Depression—Imiquimod—skin cancer	0.00102	0.00645	CcSEcCtD
Pimozide—HTR2A—blood vessel—skin cancer	0.00101	0.0131	CbGeAlD
Pimozide—Eye disorder—Vemurafenib—skin cancer	0.001	0.00637	CcSEcCtD
Pimozide—Cardiac disorder—Vemurafenib—skin cancer	0.000996	0.00632	CcSEcCtD
Pimozide—OPRK1—head—skin cancer	0.000974	0.0126	CbGeAlD
Pimozide—CYP1A2—nipple—skin cancer	0.000933	0.0121	CbGeAlD
Pimozide—Connective tissue disorder—Imiquimod—skin cancer	0.0009	0.00571	CcSEcCtD
Pimozide—CALM3—mammalian vulva—skin cancer	0.000895	0.0116	CbGeAlD
Pimozide—Asthenia—Vismodegib—skin cancer	0.000886	0.00562	CcSEcCtD
Pimozide—Visual impairment—Imiquimod—skin cancer	0.000882	0.0056	CcSEcCtD
Pimozide—Pruritus—Vismodegib—skin cancer	0.000873	0.00554	CcSEcCtD
Pimozide—HRH1—nipple—skin cancer	0.000873	0.0113	CbGeAlD
Pimozide—Eye disorder—Imiquimod—skin cancer	0.000856	0.00543	CcSEcCtD
Pimozide—CALM2—connective tissue—skin cancer	0.000853	0.0111	CbGeAlD
Pimozide—CALM1—connective tissue—skin cancer	0.000849	0.011	CbGeAlD
Pimozide—Diarrhoea—Vismodegib—skin cancer	0.000845	0.00536	CcSEcCtD
Pimozide—Amenorrhoea—Docetaxel—skin cancer	0.000827	0.00525	CcSEcCtD
Pimozide—CALM2—epithelium—skin cancer	0.00081	0.0105	CbGeAlD
Pimozide—CALM1—epithelium—skin cancer	0.000806	0.0105	CbGeAlD
Pimozide—Mental disorder—Imiquimod—skin cancer	0.000802	0.00509	CcSEcCtD
Pimozide—Myalgia—Vemurafenib—skin cancer	0.000796	0.00505	CcSEcCtD
Pimozide—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.00079	0.00501	CcSEcCtD
Pimozide—Vomiting—Vismodegib—skin cancer	0.000785	0.00498	CcSEcCtD
Pimozide—Rash—Vismodegib—skin cancer	0.000778	0.00494	CcSEcCtD
Pimozide—Dermatitis—Vismodegib—skin cancer	0.000778	0.00493	CcSEcCtD
Pimozide—Pancytopenia—Bleomycin—skin cancer	0.000772	0.0049	CcSEcCtD
Pimozide—CALM2—skin of body—skin cancer	0.00077	0.01	CbGeAlD
Pimozide—CALM1—skin of body—skin cancer	0.000767	0.00996	CbGeAlD
Pimozide—Dysphagia—Dactinomycin—skin cancer	0.000758	0.00481	CcSEcCtD
Pimozide—Nervous system disorder—Vemurafenib—skin cancer	0.000748	0.00475	CcSEcCtD
Pimozide—Skin disorder—Vemurafenib—skin cancer	0.000741	0.0047	CcSEcCtD
Pimozide—Weight decreased—Bleomycin—skin cancer	0.000735	0.00466	CcSEcCtD
Pimozide—Nausea—Vismodegib—skin cancer	0.000733	0.00465	CcSEcCtD
Pimozide—Agitation—Imiquimod—skin cancer	0.000732	0.00465	CcSEcCtD
Pimozide—HTR2A—neck—skin cancer	0.000722	0.00937	CbGeAlD
Pimozide—Pancytopenia—Dactinomycin—skin cancer	0.00072	0.00457	CcSEcCtD
Pimozide—Breast disorder—Temozolomide—skin cancer	0.000717	0.00455	CcSEcCtD
Pimozide—Syncope—Imiquimod—skin cancer	0.000715	0.00453	CcSEcCtD
Pimozide—Hypotension—Vemurafenib—skin cancer	0.000713	0.00452	CcSEcCtD
Pimozide—Palpitations—Imiquimod—skin cancer	0.000704	0.00447	CcSEcCtD
Pimozide—CALM2—mammalian vulva—skin cancer	0.000703	0.00913	CbGeAlD
Pimozide—Loss of consciousness—Imiquimod—skin cancer	0.0007	0.00444	CcSEcCtD
Pimozide—CALM1—mammalian vulva—skin cancer	0.000699	0.00908	CbGeAlD
Pimozide—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.000695	0.00441	CcSEcCtD
Pimozide—OPRM1—head—skin cancer	0.000693	0.009	CbGeAlD
Pimozide—Convulsion—Imiquimod—skin cancer	0.00069	0.00438	CcSEcCtD
Pimozide—Hypertension—Imiquimod—skin cancer	0.000688	0.00437	CcSEcCtD
Pimozide—Dysphagia—Temozolomide—skin cancer	0.000685	0.00435	CcSEcCtD
Pimozide—Myalgia—Imiquimod—skin cancer	0.000678	0.0043	CcSEcCtD
Pimozide—Chest pain—Imiquimod—skin cancer	0.000678	0.0043	CcSEcCtD
Pimozide—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.000674	0.00428	CcSEcCtD
Pimozide—Dry mouth—Imiquimod—skin cancer	0.000664	0.00421	CcSEcCtD
Pimozide—Decreased appetite—Vemurafenib—skin cancer	0.000663	0.00421	CcSEcCtD
Pimozide—ABCB1—blood vessel—skin cancer	0.000661	0.00859	CbGeAlD
Pimozide—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000658	0.00418	CcSEcCtD
Pimozide—Constipation—Vemurafenib—skin cancer	0.000652	0.00414	CcSEcCtD
Pimozide—Pancytopenia—Temozolomide—skin cancer	0.000651	0.00413	CcSEcCtD
Pimozide—Shock—Imiquimod—skin cancer	0.00064	0.00406	CcSEcCtD
Pimozide—Nervous system disorder—Imiquimod—skin cancer	0.000638	0.00405	CcSEcCtD
Pimozide—Tachycardia—Imiquimod—skin cancer	0.000635	0.00403	CcSEcCtD
Pimozide—Pollakiuria—Temozolomide—skin cancer	0.000633	0.00402	CcSEcCtD
Pimozide—Skin disorder—Imiquimod—skin cancer	0.000632	0.00401	CcSEcCtD
Pimozide—Dysphagia—Fluorouracil—skin cancer	0.000631	0.00401	CcSEcCtD
Pimozide—Erectile dysfunction—Temozolomide—skin cancer	0.000631	0.00401	CcSEcCtD
Pimozide—Agranulocytosis—Dactinomycin—skin cancer	0.000631	0.004	CcSEcCtD
Pimozide—CHRM2—head—skin cancer	0.00063	0.00819	CbGeAlD
Pimozide—Hyperhidrosis—Imiquimod—skin cancer	0.000629	0.00399	CcSEcCtD
Pimozide—Eosinophilia—Fluorouracil—skin cancer	0.000625	0.00397	CcSEcCtD
Pimozide—CALM2—lymphoid tissue—skin cancer	0.000624	0.0081	CbGeAlD
Pimozide—Weight increased—Temozolomide—skin cancer	0.000624	0.00396	CcSEcCtD
Pimozide—CALM1—lymphoid tissue—skin cancer	0.000621	0.00806	CbGeAlD
Pimozide—Weight decreased—Temozolomide—skin cancer	0.00062	0.00393	CcSEcCtD
Pimozide—Anorexia—Imiquimod—skin cancer	0.00062	0.00393	CcSEcCtD
Pimozide—HRH1—connective tissue—skin cancer	0.000619	0.00804	CbGeAlD
Pimozide—Depression—Temozolomide—skin cancer	0.000609	0.00387	CcSEcCtD
Pimozide—CALM2—female reproductive system—skin cancer	0.000602	0.00781	CbGeAlD
Pimozide—Pancytopenia—Fluorouracil—skin cancer	0.0006	0.00381	CcSEcCtD
Pimozide—CALM1—female reproductive system—skin cancer	0.000599	0.00778	CbGeAlD
Pimozide—Musculoskeletal discomfort—Imiquimod—skin cancer	0.000593	0.00376	CcSEcCtD
Pimozide—Insomnia—Imiquimod—skin cancer	0.000588	0.00373	CcSEcCtD
Pimozide—HRH1—epithelium—skin cancer	0.000588	0.00764	CbGeAlD
Pimozide—Somnolence—Imiquimod—skin cancer	0.000578	0.00367	CcSEcCtD
Pimozide—Decreased appetite—Imiquimod—skin cancer	0.000565	0.00359	CcSEcCtD
Pimozide—Gastrointestinal disorder—Imiquimod—skin cancer	0.000561	0.00356	CcSEcCtD
Pimozide—Visual disturbance—Docetaxel—skin cancer	0.000556	0.00353	CcSEcCtD
Pimozide—Asthenia—Vemurafenib—skin cancer	0.000547	0.00347	CcSEcCtD
Pimozide—KCNH2—female reproductive system—skin cancer	0.000545	0.00708	CbGeAlD
Pimozide—Pruritus—Vemurafenib—skin cancer	0.00054	0.00342	CcSEcCtD
Pimozide—Connective tissue disorder—Temozolomide—skin cancer	0.000539	0.00342	CcSEcCtD
Pimozide—Hyponatraemia—Docetaxel—skin cancer	0.000529	0.00336	CcSEcCtD
Pimozide—Visual impairment—Temozolomide—skin cancer	0.000529	0.00335	CcSEcCtD
Pimozide—Agranulocytosis—Fluorouracil—skin cancer	0.000525	0.00333	CcSEcCtD
Pimozide—Anaemia—Bleomycin—skin cancer	0.000523	0.00332	CcSEcCtD
Pimozide—Diarrhoea—Vemurafenib—skin cancer	0.000522	0.00331	CcSEcCtD
Pimozide—HTR2A—connective tissue—skin cancer	0.000517	0.00672	CbGeAlD
Pimozide—Urticaria—Imiquimod—skin cancer	0.000517	0.00328	CcSEcCtD
Pimozide—Eye disorder—Temozolomide—skin cancer	0.000513	0.00325	CcSEcCtD
Pimozide—HTR1A—head—skin cancer	0.000511	0.00664	CbGeAlD
Pimozide—HRH1—mammalian vulva—skin cancer	0.00051	0.00663	CbGeAlD
Pimozide—Cardiac disorder—Temozolomide—skin cancer	0.000509	0.00323	CcSEcCtD
Pimozide—Leukopenia—Bleomycin—skin cancer	0.000507	0.00322	CcSEcCtD
Pimozide—Dizziness—Vemurafenib—skin cancer	0.000504	0.0032	CcSEcCtD
Pimozide—CALM2—head—skin cancer	0.000503	0.00653	CbGeAlD
Pimozide—CALM1—head—skin cancer	0.0005	0.0065	CbGeAlD
Pimozide—HTR2A—epithelium—skin cancer	0.000491	0.00638	CbGeAlD
Pimozide—Anaemia—Dactinomycin—skin cancer	0.000488	0.0031	CcSEcCtD
Pimozide—Vomiting—Vemurafenib—skin cancer	0.000485	0.00308	CcSEcCtD
Pimozide—Chest pain—Bleomycin—skin cancer	0.000482	0.00306	CcSEcCtD
Pimozide—Myalgia—Bleomycin—skin cancer	0.000482	0.00306	CcSEcCtD
Pimozide—Orthostatic hypotension—Docetaxel—skin cancer	0.000482	0.00306	CcSEcCtD
Pimozide—Rash—Vemurafenib—skin cancer	0.000481	0.00305	CcSEcCtD
Pimozide—Mental disorder—Temozolomide—skin cancer	0.000481	0.00305	CcSEcCtD
Pimozide—Dermatitis—Vemurafenib—skin cancer	0.00048	0.00305	CcSEcCtD
Pimozide—Headache—Vemurafenib—skin cancer	0.000478	0.00303	CcSEcCtD
Pimozide—Breast disorder—Docetaxel—skin cancer	0.000477	0.00302	CcSEcCtD
Pimozide—Cramp muscle—Docetaxel—skin cancer	0.000475	0.00301	CcSEcCtD
Pimozide—Leukopenia—Dactinomycin—skin cancer	0.000473	0.003	CcSEcCtD
Pimozide—Asthenia—Imiquimod—skin cancer	0.000467	0.00296	CcSEcCtD
Pimozide—DRD2—head—skin cancer	0.000462	0.006	CbGeAlD
Pimozide—Pruritus—Imiquimod—skin cancer	0.00046	0.00292	CcSEcCtD
Pimozide—Dysphagia—Docetaxel—skin cancer	0.000456	0.00289	CcSEcCtD
Pimozide—KCNH2—head—skin cancer	0.000455	0.00591	CbGeAlD
Pimozide—Nausea—Vemurafenib—skin cancer	0.000453	0.00287	CcSEcCtD
Pimozide—Vision blurred—Temozolomide—skin cancer	0.00045	0.00286	CcSEcCtD
Pimozide—Myalgia—Dactinomycin—skin cancer	0.00045	0.00285	CcSEcCtD
Pimozide—CALM3—lymph node—skin cancer	0.000448	0.00582	CbGeAlD
Pimozide—Tremor—Temozolomide—skin cancer	0.000447	0.00284	CcSEcCtD
Pimozide—Diarrhoea—Imiquimod—skin cancer	0.000445	0.00282	CcSEcCtD
Pimozide—Anaemia—Temozolomide—skin cancer	0.000441	0.0028	CcSEcCtD
Pimozide—Anorexia—Bleomycin—skin cancer	0.00044	0.00279	CcSEcCtD
Pimozide—Agitation—Temozolomide—skin cancer	0.000439	0.00278	CcSEcCtD
Pimozide—HRH1—female reproductive system—skin cancer	0.000437	0.00567	CbGeAlD
Pimozide—CYP2E1—lymphoid tissue—skin cancer	0.000435	0.00565	CbGeAlD
Pimozide—Pancytopenia—Docetaxel—skin cancer	0.000433	0.00275	CcSEcCtD
Pimozide—Hypotension—Bleomycin—skin cancer	0.000432	0.00274	CcSEcCtD
Pimozide—Dizziness—Imiquimod—skin cancer	0.00043	0.00273	CcSEcCtD
Pimozide—Leukopenia—Temozolomide—skin cancer	0.000427	0.00271	CcSEcCtD
Pimozide—Palpitations—Temozolomide—skin cancer	0.000422	0.00268	CcSEcCtD
Pimozide—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000421	0.00267	CcSEcCtD
Pimozide—CYP2E1—female reproductive system—skin cancer	0.00042	0.00545	CbGeAlD
Pimozide—Weight increased—Docetaxel—skin cancer	0.000415	0.00263	CcSEcCtD
Pimozide—Vision blurred—Fluorouracil—skin cancer	0.000415	0.00263	CcSEcCtD
Pimozide—Convulsion—Temozolomide—skin cancer	0.000414	0.00263	CcSEcCtD
Pimozide—Vomiting—Imiquimod—skin cancer	0.000414	0.00262	CcSEcCtD
Pimozide—Weight decreased—Docetaxel—skin cancer	0.000412	0.00262	CcSEcCtD
Pimozide—Hypertension—Temozolomide—skin cancer	0.000412	0.00262	CcSEcCtD
Pimozide—Anorexia—Dactinomycin—skin cancer	0.000411	0.00261	CcSEcCtD
Pimozide—Rash—Imiquimod—skin cancer	0.00041	0.0026	CcSEcCtD
Pimozide—Dermatitis—Imiquimod—skin cancer	0.00041	0.0026	CcSEcCtD
Pimozide—Headache—Imiquimod—skin cancer	0.000407	0.00259	CcSEcCtD
Pimozide—Anaemia—Fluorouracil—skin cancer	0.000407	0.00258	CcSEcCtD
Pimozide—Myalgia—Temozolomide—skin cancer	0.000407	0.00258	CcSEcCtD
Pimozide—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000404	0.00256	CcSEcCtD
Pimozide—Decreased appetite—Bleomycin—skin cancer	0.000402	0.00255	CcSEcCtD
Pimozide—Dry mouth—Temozolomide—skin cancer	0.000398	0.00252	CcSEcCtD
Pimozide—Leukopenia—Fluorouracil—skin cancer	0.000394	0.0025	CcSEcCtD
Pimozide—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000393	0.00249	CcSEcCtD
Pimozide—Nausea—Imiquimod—skin cancer	0.000386	0.00245	CcSEcCtD
Pimozide—Nervous system disorder—Temozolomide—skin cancer	0.000382	0.00243	CcSEcCtD
Pimozide—Convulsion—Fluorouracil—skin cancer	0.000381	0.00242	CcSEcCtD
Pimozide—Agranulocytosis—Docetaxel—skin cancer	0.000379	0.00241	CcSEcCtD
Pimozide—Skin disorder—Temozolomide—skin cancer	0.000379	0.0024	CcSEcCtD
Pimozide—Hyperhidrosis—Temozolomide—skin cancer	0.000377	0.00239	CcSEcCtD
Pimozide—Myalgia—Fluorouracil—skin cancer	0.000375	0.00238	CcSEcCtD
Pimozide—Chest pain—Fluorouracil—skin cancer	0.000375	0.00238	CcSEcCtD
Pimozide—Decreased appetite—Dactinomycin—skin cancer	0.000375	0.00238	CcSEcCtD
Pimozide—Anorexia—Temozolomide—skin cancer	0.000372	0.00236	CcSEcCtD
Pimozide—Urticaria—Bleomycin—skin cancer	0.000367	0.00233	CcSEcCtD
Pimozide—HRH1—head—skin cancer	0.000365	0.00474	CbGeAlD
Pimozide—HTR2A—female reproductive system—skin cancer	0.000365	0.00474	CbGeAlD
Pimozide—Connective tissue disorder—Docetaxel—skin cancer	0.000359	0.00227	CcSEcCtD
Pimozide—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000355	0.00225	CcSEcCtD
Pimozide—Insomnia—Temozolomide—skin cancer	0.000353	0.00224	CcSEcCtD
Pimozide—Nervous system disorder—Fluorouracil—skin cancer	0.000352	0.00223	CcSEcCtD
Pimozide—CALM2—lymph node—skin cancer	0.000352	0.00457	CbGeAlD
Pimozide—Visual impairment—Docetaxel—skin cancer	0.000352	0.00223	CcSEcCtD
Pimozide—CYP2E1—head—skin cancer	0.000351	0.00455	CbGeAlD
Pimozide—Tachycardia—Fluorouracil—skin cancer	0.00035	0.00222	CcSEcCtD
Pimozide—CALM1—lymph node—skin cancer	0.00035	0.00455	CbGeAlD
Pimozide—Somnolence—Temozolomide—skin cancer	0.000346	0.0022	CcSEcCtD
Pimozide—Anorexia—Fluorouracil—skin cancer	0.000342	0.00217	CcSEcCtD
Pimozide—Eye disorder—Docetaxel—skin cancer	0.000341	0.00216	CcSEcCtD
Pimozide—Decreased appetite—Temozolomide—skin cancer	0.000339	0.00215	CcSEcCtD
Pimozide—Cardiac disorder—Docetaxel—skin cancer	0.000339	0.00215	CcSEcCtD
Pimozide—CYP3A4—female reproductive system—skin cancer	0.000338	0.00439	CbGeAlD
Pimozide—Gastrointestinal disorder—Temozolomide—skin cancer	0.000336	0.00214	CcSEcCtD
Pimozide—Hypotension—Fluorouracil—skin cancer	0.000336	0.00213	CcSEcCtD
Pimozide—Constipation—Temozolomide—skin cancer	0.000333	0.00211	CcSEcCtD
Pimozide—CYP2D6—female reproductive system—skin cancer	0.000332	0.00432	CbGeAlD
Pimozide—Asthenia—Bleomycin—skin cancer	0.000332	0.0021	CcSEcCtD
Pimozide—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000327	0.00208	CcSEcCtD
Pimozide—Pruritus—Bleomycin—skin cancer	0.000327	0.00207	CcSEcCtD
Pimozide—Insomnia—Fluorouracil—skin cancer	0.000325	0.00206	CcSEcCtD
Pimozide—ABCB1—epithelium—skin cancer	0.000322	0.00418	CbGeAlD
Pimozide—Mental disorder—Docetaxel—skin cancer	0.00032	0.00203	CcSEcCtD
Pimozide—Somnolence—Fluorouracil—skin cancer	0.000319	0.00203	CcSEcCtD
Pimozide—KCNH2—lymph node—skin cancer	0.000319	0.00414	CbGeAlD
Pimozide—Decreased appetite—Fluorouracil—skin cancer	0.000312	0.00198	CcSEcCtD
Pimozide—Gastrointestinal disorder—Fluorouracil—skin cancer	0.00031	0.00197	CcSEcCtD
Pimozide—Urticaria—Temozolomide—skin cancer	0.00031	0.00196	CcSEcCtD
Pimozide—Asthenia—Dactinomycin—skin cancer	0.000309	0.00196	CcSEcCtD
Pimozide—Muscle spasms—Docetaxel—skin cancer	0.000305	0.00194	CcSEcCtD
Pimozide—HTR2A—head—skin cancer	0.000305	0.00396	CbGeAlD
Pimozide—Diarrhoea—Dactinomycin—skin cancer	0.000295	0.00187	CcSEcCtD
Pimozide—Vomiting—Bleomycin—skin cancer	0.000294	0.00186	CcSEcCtD
Pimozide—Anaemia—Docetaxel—skin cancer	0.000294	0.00186	CcSEcCtD
Pimozide—Rash—Bleomycin—skin cancer	0.000291	0.00185	CcSEcCtD
Pimozide—Dermatitis—Bleomycin—skin cancer	0.000291	0.00185	CcSEcCtD
Pimozide—Urticaria—Fluorouracil—skin cancer	0.000285	0.00181	CcSEcCtD
Pimozide—Syncope—Docetaxel—skin cancer	0.000285	0.00181	CcSEcCtD
Pimozide—Leukopenia—Docetaxel—skin cancer	0.000284	0.0018	CcSEcCtD
Pimozide—Palpitations—Docetaxel—skin cancer	0.000281	0.00178	CcSEcCtD
Pimozide—Asthenia—Temozolomide—skin cancer	0.00028	0.00177	CcSEcCtD
Pimozide—ABCB1—mammalian vulva—skin cancer	0.000279	0.00363	CbGeAlD
Pimozide—Loss of consciousness—Docetaxel—skin cancer	0.000279	0.00177	CcSEcCtD
Pimozide—CYP2D6—head—skin cancer	0.000278	0.00361	CbGeAlD
Pimozide—Pruritus—Temozolomide—skin cancer	0.000276	0.00175	CcSEcCtD
Pimozide—Convulsion—Docetaxel—skin cancer	0.000275	0.00175	CcSEcCtD
Pimozide—Nausea—Bleomycin—skin cancer	0.000274	0.00174	CcSEcCtD
Pimozide—Hypertension—Docetaxel—skin cancer	0.000274	0.00174	CcSEcCtD
Pimozide—Vomiting—Dactinomycin—skin cancer	0.000274	0.00174	CcSEcCtD
Pimozide—Rash—Dactinomycin—skin cancer	0.000272	0.00172	CcSEcCtD
Pimozide—Chest pain—Docetaxel—skin cancer	0.00027	0.00172	CcSEcCtD
Pimozide—Myalgia—Docetaxel—skin cancer	0.00027	0.00172	CcSEcCtD
Pimozide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000269	0.0017	CcSEcCtD
Pimozide—Diarrhoea—Temozolomide—skin cancer	0.000267	0.00169	CcSEcCtD
Pimozide—Dry mouth—Docetaxel—skin cancer	0.000264	0.00168	CcSEcCtD
Pimozide—Dizziness—Temozolomide—skin cancer	0.000258	0.00164	CcSEcCtD
Pimozide—Nausea—Dactinomycin—skin cancer	0.000256	0.00162	CcSEcCtD
Pimozide—HRH1—lymph node—skin cancer	0.000256	0.00332	CbGeAlD
Pimozide—Shock—Docetaxel—skin cancer	0.000255	0.00162	CcSEcCtD
Pimozide—Nervous system disorder—Docetaxel—skin cancer	0.000254	0.00161	CcSEcCtD
Pimozide—Pruritus—Fluorouracil—skin cancer	0.000254	0.00161	CcSEcCtD
Pimozide—Tachycardia—Docetaxel—skin cancer	0.000253	0.00161	CcSEcCtD
Pimozide—Skin disorder—Docetaxel—skin cancer	0.000252	0.0016	CcSEcCtD
Pimozide—ABCB1—lymphoid tissue—skin cancer	0.000248	0.00322	CbGeAlD
Pimozide—Vomiting—Temozolomide—skin cancer	0.000248	0.00157	CcSEcCtD
Pimozide—Anorexia—Docetaxel—skin cancer	0.000247	0.00157	CcSEcCtD
Pimozide—Rash—Temozolomide—skin cancer	0.000246	0.00156	CcSEcCtD
Pimozide—Diarrhoea—Fluorouracil—skin cancer	0.000246	0.00156	CcSEcCtD
Pimozide—Dermatitis—Temozolomide—skin cancer	0.000246	0.00156	CcSEcCtD
Pimozide—Headache—Temozolomide—skin cancer	0.000244	0.00155	CcSEcCtD
Pimozide—Hypotension—Docetaxel—skin cancer	0.000242	0.00154	CcSEcCtD
Pimozide—ABCB1—female reproductive system—skin cancer	0.000239	0.00311	CbGeAlD
Pimozide—Dizziness—Fluorouracil—skin cancer	0.000237	0.00151	CcSEcCtD
Pimozide—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000236	0.0015	CcSEcCtD
Pimozide—Insomnia—Docetaxel—skin cancer	0.000234	0.00149	CcSEcCtD
Pimozide—Nausea—Temozolomide—skin cancer	0.000232	0.00147	CcSEcCtD
Pimozide—Somnolence—Docetaxel—skin cancer	0.00023	0.00146	CcSEcCtD
Pimozide—Vomiting—Fluorouracil—skin cancer	0.000228	0.00145	CcSEcCtD
Pimozide—Rash—Fluorouracil—skin cancer	0.000226	0.00144	CcSEcCtD
Pimozide—Dermatitis—Fluorouracil—skin cancer	0.000226	0.00144	CcSEcCtD
Pimozide—Decreased appetite—Docetaxel—skin cancer	0.000225	0.00143	CcSEcCtD
Pimozide—Headache—Fluorouracil—skin cancer	0.000225	0.00143	CcSEcCtD
Pimozide—Gastrointestinal disorder—Docetaxel—skin cancer	0.000224	0.00142	CcSEcCtD
Pimozide—Constipation—Docetaxel—skin cancer	0.000222	0.00141	CcSEcCtD
Pimozide—Nausea—Fluorouracil—skin cancer	0.000213	0.00135	CcSEcCtD
Pimozide—ABCB1—head—skin cancer	0.0002	0.00259	CbGeAlD
Pimozide—Asthenia—Docetaxel—skin cancer	0.000186	0.00118	CcSEcCtD
Pimozide—Pruritus—Docetaxel—skin cancer	0.000183	0.00116	CcSEcCtD
Pimozide—Diarrhoea—Docetaxel—skin cancer	0.000177	0.00113	CcSEcCtD
Pimozide—Dizziness—Docetaxel—skin cancer	0.000171	0.00109	CcSEcCtD
Pimozide—Vomiting—Docetaxel—skin cancer	0.000165	0.00105	CcSEcCtD
Pimozide—Rash—Docetaxel—skin cancer	0.000163	0.00104	CcSEcCtD
Pimozide—Dermatitis—Docetaxel—skin cancer	0.000163	0.00104	CcSEcCtD
Pimozide—Headache—Docetaxel—skin cancer	0.000162	0.00103	CcSEcCtD
Pimozide—Nausea—Docetaxel—skin cancer	0.000154	0.000977	CcSEcCtD
Pimozide—ABCB1—lymph node—skin cancer	0.00014	0.00182	CbGeAlD
Pimozide—CALM1—Signaling Pathways—RASA1—skin cancer	1.79e-05	0.000233	CbGpPWpGaD
Pimozide—CALM3—Signaling Pathways—PTCH1—skin cancer	1.77e-05	0.00023	CbGpPWpGaD
Pimozide—CALM3—Signaling Pathways—SMO—skin cancer	1.77e-05	0.00023	CbGpPWpGaD
Pimozide—CALM3—Neuronal System—HRAS—skin cancer	1.75e-05	0.000228	CbGpPWpGaD
Pimozide—CYP2C19—Metabolism—ENO2—skin cancer	1.73e-05	0.000225	CbGpPWpGaD
Pimozide—CALM3—Signaling by NGF—HRAS—skin cancer	1.72e-05	0.000224	CbGpPWpGaD
Pimozide—CALM3—Signaling Pathways—PTGER4—skin cancer	1.72e-05	0.000224	CbGpPWpGaD
Pimozide—CALM2—Signaling Pathways—SMO—skin cancer	1.71e-05	0.000223	CbGpPWpGaD
Pimozide—CALM1—Signaling Pathways—PTCH1—skin cancer	1.71e-05	0.000223	CbGpPWpGaD
Pimozide—CALM1—Signaling Pathways—SMO—skin cancer	1.71e-05	0.000223	CbGpPWpGaD
Pimozide—CALM2—Signaling Pathways—PTCH1—skin cancer	1.71e-05	0.000223	CbGpPWpGaD
Pimozide—CALM1—Neuronal System—HRAS—skin cancer	1.7e-05	0.000221	CbGpPWpGaD
Pimozide—CALM2—Neuronal System—HRAS—skin cancer	1.7e-05	0.000221	CbGpPWpGaD
Pimozide—ABCB1—Metabolism—ENO2—skin cancer	1.69e-05	0.00022	CbGpPWpGaD
Pimozide—CALM1—Signaling by NGF—HRAS—skin cancer	1.66e-05	0.000217	CbGpPWpGaD
Pimozide—CALM2—Signaling by NGF—HRAS—skin cancer	1.66e-05	0.000217	CbGpPWpGaD
Pimozide—CALM2—Signaling Pathways—PTGER4—skin cancer	1.66e-05	0.000217	CbGpPWpGaD
Pimozide—CALM1—Signaling Pathways—PTGER4—skin cancer	1.66e-05	0.000217	CbGpPWpGaD
Pimozide—CALM3—Signaling by NGF—IL6—skin cancer	1.65e-05	0.000214	CbGpPWpGaD
Pimozide—OPRM1—Signaling Pathways—TERT—skin cancer	1.64e-05	0.000213	CbGpPWpGaD
Pimozide—OPRK1—Signaling by GPCR—NRAS—skin cancer	1.63e-05	0.000213	CbGpPWpGaD
Pimozide—DRD3—Signaling Pathways—TERT—skin cancer	1.62e-05	0.000211	CbGpPWpGaD
Pimozide—HTR6—Signaling by GPCR—NRAS—skin cancer	1.61e-05	0.00021	CbGpPWpGaD
Pimozide—CALM1—Signaling by NGF—IL6—skin cancer	1.59e-05	0.000207	CbGpPWpGaD
Pimozide—CALM2—Signaling by NGF—IL6—skin cancer	1.59e-05	0.000207	CbGpPWpGaD
Pimozide—CYP2D6—Metabolism—ENO2—skin cancer	1.59e-05	0.000207	CbGpPWpGaD
Pimozide—CALM3—Disease—ERCC2—skin cancer	1.55e-05	0.000201	CbGpPWpGaD
Pimozide—OPRK1—Signaling Pathways—BRAF—skin cancer	1.54e-05	0.0002	CbGpPWpGaD
Pimozide—CYP3A4—Metabolism—CSPG4—skin cancer	1.53e-05	0.000199	CbGpPWpGaD
Pimozide—CALM3—Signaling Pathways—FOXO4—skin cancer	1.52e-05	0.000198	CbGpPWpGaD
Pimozide—HTR6—Signaling Pathways—BRAF—skin cancer	1.51e-05	0.000197	CbGpPWpGaD
Pimozide—CALM2—Disease—ERCC2—skin cancer	1.49e-05	0.000195	CbGpPWpGaD
Pimozide—CALM1—Disease—ERCC2—skin cancer	1.49e-05	0.000195	CbGpPWpGaD
Pimozide—CALM3—Hemostasis—NRAS—skin cancer	1.49e-05	0.000194	CbGpPWpGaD
Pimozide—CALM2—Signaling Pathways—FOXO4—skin cancer	1.47e-05	0.000191	CbGpPWpGaD
Pimozide—CALM1—Signaling Pathways—FOXO4—skin cancer	1.47e-05	0.000191	CbGpPWpGaD
Pimozide—CALM3—Disease—TERT—skin cancer	1.45e-05	0.000189	CbGpPWpGaD
Pimozide—CALM1—Hemostasis—NRAS—skin cancer	1.44e-05	0.000188	CbGpPWpGaD
Pimozide—CALM2—Hemostasis—NRAS—skin cancer	1.44e-05	0.000188	CbGpPWpGaD
Pimozide—HTR1A—Signaling Pathways—TERT—skin cancer	1.41e-05	0.000184	CbGpPWpGaD
Pimozide—OPRK1—Signaling by GPCR—KRAS—skin cancer	1.41e-05	0.000183	CbGpPWpGaD
Pimozide—CALM1—Disease—TERT—skin cancer	1.4e-05	0.000183	CbGpPWpGaD
Pimozide—CALM2—Disease—TERT—skin cancer	1.4e-05	0.000183	CbGpPWpGaD
Pimozide—HTR6—Signaling by GPCR—KRAS—skin cancer	1.39e-05	0.00018	CbGpPWpGaD
Pimozide—OPRM1—Signaling by GPCR—NRAS—skin cancer	1.38e-05	0.00018	CbGpPWpGaD
Pimozide—DRD3—Signaling by GPCR—NRAS—skin cancer	1.37e-05	0.000178	CbGpPWpGaD
Pimozide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.35e-05	0.000176	CbGpPWpGaD
Pimozide—CYP1A2—Metabolism—ENO2—skin cancer	1.35e-05	0.000176	CbGpPWpGaD
Pimozide—CALM3—Innate Immune System—NRAS—skin cancer	1.34e-05	0.000175	CbGpPWpGaD
Pimozide—CYP2E1—Metabolism—ERCC2—skin cancer	1.3e-05	0.00017	CbGpPWpGaD
Pimozide—CYP3A5—Metabolism—ERCC2—skin cancer	1.3e-05	0.000169	CbGpPWpGaD
Pimozide—OPRM1—Signaling Pathways—BRAF—skin cancer	1.3e-05	0.000169	CbGpPWpGaD
Pimozide—CALM1—Innate Immune System—NRAS—skin cancer	1.3e-05	0.000169	CbGpPWpGaD
Pimozide—CALM2—Innate Immune System—NRAS—skin cancer	1.3e-05	0.000169	CbGpPWpGaD
Pimozide—CALM3—Metabolism—ERCC2—skin cancer	1.29e-05	0.000169	CbGpPWpGaD
Pimozide—CALM3—Adaptive Immune System—NRAS—skin cancer	1.29e-05	0.000168	CbGpPWpGaD
Pimozide—DRD3—Signaling Pathways—BRAF—skin cancer	1.29e-05	0.000167	CbGpPWpGaD
Pimozide—CALM3—Hemostasis—KRAS—skin cancer	1.28e-05	0.000167	CbGpPWpGaD
Pimozide—CALM1—Metabolism—ERCC2—skin cancer	1.25e-05	0.000163	CbGpPWpGaD
Pimozide—CALM2—Metabolism—ERCC2—skin cancer	1.25e-05	0.000163	CbGpPWpGaD
Pimozide—CALM2—Adaptive Immune System—NRAS—skin cancer	1.25e-05	0.000162	CbGpPWpGaD
Pimozide—CALM1—Adaptive Immune System—NRAS—skin cancer	1.25e-05	0.000162	CbGpPWpGaD
Pimozide—DRD2—Signaling Pathways—TERT—skin cancer	1.24e-05	0.000162	CbGpPWpGaD
Pimozide—CALM2—Hemostasis—KRAS—skin cancer	1.24e-05	0.000161	CbGpPWpGaD
Pimozide—CALM1—Hemostasis—KRAS—skin cancer	1.24e-05	0.000161	CbGpPWpGaD
Pimozide—HTR2A—Signaling Pathways—TERT—skin cancer	1.22e-05	0.000159	CbGpPWpGaD
Pimozide—HRH1—Signaling Pathways—TERT—skin cancer	1.22e-05	0.000159	CbGpPWpGaD
Pimozide—CHRM2—Signaling Pathways—TERT—skin cancer	1.2e-05	0.000156	CbGpPWpGaD
Pimozide—OPRK1—Signaling by GPCR—HRAS—skin cancer	1.2e-05	0.000156	CbGpPWpGaD
Pimozide—HTR1A—Signaling by GPCR—NRAS—skin cancer	1.19e-05	0.000155	CbGpPWpGaD
Pimozide—OPRM1—Signaling by GPCR—KRAS—skin cancer	1.19e-05	0.000155	CbGpPWpGaD
Pimozide—HTR6—Signaling by GPCR—HRAS—skin cancer	1.18e-05	0.000153	CbGpPWpGaD
Pimozide—DRD3—Signaling by GPCR—KRAS—skin cancer	1.18e-05	0.000153	CbGpPWpGaD
Pimozide—CALM3—Innate Immune System—KRAS—skin cancer	1.15e-05	0.00015	CbGpPWpGaD
Pimozide—CALM3—Disease—BRAF—skin cancer	1.15e-05	0.000149	CbGpPWpGaD
Pimozide—OPRK1—Signaling by GPCR—IL6—skin cancer	1.14e-05	0.000149	CbGpPWpGaD
Pimozide—CALM3—Hemostasis—TP53—skin cancer	1.14e-05	0.000148	CbGpPWpGaD
Pimozide—HTR6—Signaling by GPCR—IL6—skin cancer	1.13e-05	0.000147	CbGpPWpGaD
Pimozide—HTR1A—Signaling Pathways—BRAF—skin cancer	1.12e-05	0.000146	CbGpPWpGaD
Pimozide—CALM1—Innate Immune System—KRAS—skin cancer	1.12e-05	0.000145	CbGpPWpGaD
Pimozide—CALM2—Innate Immune System—KRAS—skin cancer	1.12e-05	0.000145	CbGpPWpGaD
Pimozide—CALM2—Disease—BRAF—skin cancer	1.11e-05	0.000145	CbGpPWpGaD
Pimozide—CALM1—Disease—BRAF—skin cancer	1.11e-05	0.000145	CbGpPWpGaD
Pimozide—CALM3—Adaptive Immune System—KRAS—skin cancer	1.11e-05	0.000144	CbGpPWpGaD
Pimozide—CALM1—Hemostasis—TP53—skin cancer	1.1e-05	0.000144	CbGpPWpGaD
Pimozide—CALM2—Hemostasis—TP53—skin cancer	1.1e-05	0.000144	CbGpPWpGaD
Pimozide—CALM3—Hemostasis—HRAS—skin cancer	1.09e-05	0.000142	CbGpPWpGaD
Pimozide—CYP3A7—Metabolism—PTGS2—skin cancer	1.08e-05	0.00014	CbGpPWpGaD
Pimozide—CALM2—Adaptive Immune System—KRAS—skin cancer	1.07e-05	0.00014	CbGpPWpGaD
Pimozide—CALM1—Adaptive Immune System—KRAS—skin cancer	1.07e-05	0.00014	CbGpPWpGaD
Pimozide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.05e-05	0.000137	CbGpPWpGaD
Pimozide—CALM2—Hemostasis—HRAS—skin cancer	1.05e-05	0.000137	CbGpPWpGaD
Pimozide—CALM1—Hemostasis—HRAS—skin cancer	1.05e-05	0.000137	CbGpPWpGaD
Pimozide—DRD2—Signaling by GPCR—NRAS—skin cancer	1.05e-05	0.000136	CbGpPWpGaD
Pimozide—CYP3A4—Metabolism—ENO2—skin cancer	1.04e-05	0.000135	CbGpPWpGaD
Pimozide—HTR2A—Signaling by GPCR—NRAS—skin cancer	1.03e-05	0.000134	CbGpPWpGaD
Pimozide—HRH1—Signaling by GPCR—NRAS—skin cancer	1.03e-05	0.000134	CbGpPWpGaD
Pimozide—HTR1A—Signaling by GPCR—KRAS—skin cancer	1.03e-05	0.000134	CbGpPWpGaD
Pimozide—CALM3—Signaling Pathways—TERT—skin cancer	1.01e-05	0.000132	CbGpPWpGaD
Pimozide—CHRM2—Signaling by GPCR—NRAS—skin cancer	1.01e-05	0.000132	CbGpPWpGaD
Pimozide—OPRM1—Signaling by GPCR—HRAS—skin cancer	1.01e-05	0.000132	CbGpPWpGaD
Pimozide—CYP2C19—Metabolism—ERCC2—skin cancer	1e-05	0.000131	CbGpPWpGaD
Pimozide—DRD3—Signaling by GPCR—HRAS—skin cancer	1e-05	0.00013	CbGpPWpGaD
Pimozide—DRD2—Signaling Pathways—BRAF—skin cancer	9.83e-06	0.000128	CbGpPWpGaD
Pimozide—CALM1—Signaling Pathways—TERT—skin cancer	9.81e-06	0.000128	CbGpPWpGaD
Pimozide—CALM2—Signaling Pathways—TERT—skin cancer	9.81e-06	0.000128	CbGpPWpGaD
Pimozide—CALM3—Innate Immune System—HRAS—skin cancer	9.81e-06	0.000128	CbGpPWpGaD
Pimozide—ABCB1—Metabolism—ERCC2—skin cancer	9.81e-06	0.000128	CbGpPWpGaD
Pimozide—HTR2A—Signaling Pathways—BRAF—skin cancer	9.68e-06	0.000126	CbGpPWpGaD
Pimozide—OPRM1—Signaling by GPCR—IL6—skin cancer	9.67e-06	0.000126	CbGpPWpGaD
Pimozide—HRH1—Signaling Pathways—BRAF—skin cancer	9.66e-06	0.000126	CbGpPWpGaD
Pimozide—OPRK1—Signaling Pathways—NRAS—skin cancer	9.65e-06	0.000126	CbGpPWpGaD
Pimozide—DRD3—Signaling by GPCR—IL6—skin cancer	9.57e-06	0.000125	CbGpPWpGaD
Pimozide—HTR6—Signaling Pathways—NRAS—skin cancer	9.51e-06	0.000124	CbGpPWpGaD
Pimozide—CHRM2—Signaling Pathways—BRAF—skin cancer	9.5e-06	0.000124	CbGpPWpGaD
Pimozide—CALM1—Innate Immune System—HRAS—skin cancer	9.49e-06	0.000124	CbGpPWpGaD
Pimozide—CALM2—Innate Immune System—HRAS—skin cancer	9.49e-06	0.000124	CbGpPWpGaD
Pimozide—CALM3—Adaptive Immune System—HRAS—skin cancer	9.42e-06	0.000123	CbGpPWpGaD
Pimozide—CALM3—Innate Immune System—IL6—skin cancer	9.39e-06	0.000122	CbGpPWpGaD
Pimozide—CALM3—Disease—PTGS2—skin cancer	9.27e-06	0.000121	CbGpPWpGaD
Pimozide—CYP2D6—Metabolism—ERCC2—skin cancer	9.24e-06	0.00012	CbGpPWpGaD
Pimozide—CALM2—Adaptive Immune System—HRAS—skin cancer	9.11e-06	0.000119	CbGpPWpGaD
Pimozide—CALM1—Adaptive Immune System—HRAS—skin cancer	9.11e-06	0.000119	CbGpPWpGaD
Pimozide—CALM2—Innate Immune System—IL6—skin cancer	9.08e-06	0.000118	CbGpPWpGaD
Pimozide—CALM1—Innate Immune System—IL6—skin cancer	9.08e-06	0.000118	CbGpPWpGaD
Pimozide—DRD2—Signaling by GPCR—KRAS—skin cancer	9.01e-06	0.000117	CbGpPWpGaD
Pimozide—CALM2—Disease—PTGS2—skin cancer	8.96e-06	0.000117	CbGpPWpGaD
Pimozide—CALM1—Disease—PTGS2—skin cancer	8.96e-06	0.000117	CbGpPWpGaD
Pimozide—HTR2A—Signaling by GPCR—KRAS—skin cancer	8.86e-06	0.000115	CbGpPWpGaD
Pimozide—HRH1—Signaling by GPCR—KRAS—skin cancer	8.84e-06	0.000115	CbGpPWpGaD
Pimozide—HTR1A—Signaling by GPCR—HRAS—skin cancer	8.72e-06	0.000114	CbGpPWpGaD
Pimozide—CHRM2—Signaling by GPCR—KRAS—skin cancer	8.7e-06	0.000113	CbGpPWpGaD
Pimozide—CALM3—Signaling by GPCR—NRAS—skin cancer	8.55e-06	0.000111	CbGpPWpGaD
Pimozide—HTR1A—Signaling by GPCR—IL6—skin cancer	8.34e-06	0.000109	CbGpPWpGaD
Pimozide—OPRK1—Signaling Pathways—KRAS—skin cancer	8.31e-06	0.000108	CbGpPWpGaD
Pimozide—CALM2—Signaling by GPCR—NRAS—skin cancer	8.27e-06	0.000108	CbGpPWpGaD
Pimozide—CALM1—Signaling by GPCR—NRAS—skin cancer	8.27e-06	0.000108	CbGpPWpGaD
Pimozide—HTR6—Signaling Pathways—KRAS—skin cancer	8.19e-06	0.000107	CbGpPWpGaD
Pimozide—OPRM1—Signaling Pathways—NRAS—skin cancer	8.16e-06	0.000106	CbGpPWpGaD
Pimozide—DRD3—Signaling Pathways—NRAS—skin cancer	8.08e-06	0.000105	CbGpPWpGaD
Pimozide—CALM3—Signaling Pathways—BRAF—skin cancer	8.03e-06	0.000105	CbGpPWpGaD
Pimozide—CYP1A2—Metabolism—ERCC2—skin cancer	7.83e-06	0.000102	CbGpPWpGaD
Pimozide—CYP2E1—Metabolism—PTGS2—skin cancer	7.81e-06	0.000102	CbGpPWpGaD
Pimozide—CALM3—Immune System—NRAS—skin cancer	7.81e-06	0.000102	CbGpPWpGaD
Pimozide—CYP3A5—Metabolism—PTGS2—skin cancer	7.79e-06	0.000102	CbGpPWpGaD
Pimozide—CALM1—Signaling Pathways—BRAF—skin cancer	7.77e-06	0.000101	CbGpPWpGaD
Pimozide—CALM2—Signaling Pathways—BRAF—skin cancer	7.77e-06	0.000101	CbGpPWpGaD
Pimozide—CALM3—Metabolism—PTGS2—skin cancer	7.76e-06	0.000101	CbGpPWpGaD
Pimozide—DRD2—Signaling by GPCR—HRAS—skin cancer	7.65e-06	9.97e-05	CbGpPWpGaD
Pimozide—CALM2—Immune System—NRAS—skin cancer	7.55e-06	9.84e-05	CbGpPWpGaD
Pimozide—CALM1—Immune System—NRAS—skin cancer	7.55e-06	9.84e-05	CbGpPWpGaD
Pimozide—HTR2A—Signaling by GPCR—HRAS—skin cancer	7.53e-06	9.81e-05	CbGpPWpGaD
Pimozide—HRH1—Signaling by GPCR—HRAS—skin cancer	7.52e-06	9.79e-05	CbGpPWpGaD
Pimozide—CALM2—Metabolism—PTGS2—skin cancer	7.51e-06	9.78e-05	CbGpPWpGaD
Pimozide—CALM1—Metabolism—PTGS2—skin cancer	7.51e-06	9.78e-05	CbGpPWpGaD
Pimozide—CHRM2—Signaling by GPCR—HRAS—skin cancer	7.39e-06	9.63e-05	CbGpPWpGaD
Pimozide—OPRK1—Signaling Pathways—TP53—skin cancer	7.38e-06	9.61e-05	CbGpPWpGaD
Pimozide—CALM3—Signaling by GPCR—KRAS—skin cancer	7.36e-06	9.58e-05	CbGpPWpGaD
Pimozide—DRD2—Signaling by GPCR—IL6—skin cancer	7.33e-06	9.54e-05	CbGpPWpGaD
Pimozide—HTR6—Signaling Pathways—TP53—skin cancer	7.27e-06	9.48e-05	CbGpPWpGaD
Pimozide—CALM3—Disease—NRAS—skin cancer	7.21e-06	9.39e-05	CbGpPWpGaD
Pimozide—HTR2A—Signaling by GPCR—IL6—skin cancer	7.21e-06	9.39e-05	CbGpPWpGaD
Pimozide—HRH1—Signaling by GPCR—IL6—skin cancer	7.19e-06	9.37e-05	CbGpPWpGaD
Pimozide—CALM1—Signaling by GPCR—KRAS—skin cancer	7.12e-06	9.27e-05	CbGpPWpGaD
Pimozide—CALM2—Signaling by GPCR—KRAS—skin cancer	7.12e-06	9.27e-05	CbGpPWpGaD
Pimozide—CHRM2—Signaling by GPCR—IL6—skin cancer	7.08e-06	9.22e-05	CbGpPWpGaD
Pimozide—OPRK1—Signaling Pathways—HRAS—skin cancer	7.06e-06	9.2e-05	CbGpPWpGaD
Pimozide—HTR1A—Signaling Pathways—NRAS—skin cancer	7.04e-06	9.17e-05	CbGpPWpGaD
Pimozide—OPRM1—Signaling Pathways—KRAS—skin cancer	7.02e-06	9.14e-05	CbGpPWpGaD
Pimozide—CALM1—Disease—NRAS—skin cancer	6.97e-06	9.08e-05	CbGpPWpGaD
Pimozide—CALM2—Disease—NRAS—skin cancer	6.97e-06	9.08e-05	CbGpPWpGaD
Pimozide—HTR6—Signaling Pathways—HRAS—skin cancer	6.96e-06	9.06e-05	CbGpPWpGaD
Pimozide—DRD3—Signaling Pathways—KRAS—skin cancer	6.95e-06	9.06e-05	CbGpPWpGaD
Pimozide—OPRK1—Signaling Pathways—IL6—skin cancer	6.76e-06	8.8e-05	CbGpPWpGaD
Pimozide—CALM3—Immune System—KRAS—skin cancer	6.72e-06	8.75e-05	CbGpPWpGaD
Pimozide—HTR6—Signaling Pathways—IL6—skin cancer	6.66e-06	8.67e-05	CbGpPWpGaD
Pimozide—CALM2—Immune System—KRAS—skin cancer	6.5e-06	8.47e-05	CbGpPWpGaD
Pimozide—CALM1—Immune System—KRAS—skin cancer	6.5e-06	8.47e-05	CbGpPWpGaD
Pimozide—CALM3—Signaling by GPCR—HRAS—skin cancer	6.25e-06	8.14e-05	CbGpPWpGaD
Pimozide—OPRM1—Signaling Pathways—TP53—skin cancer	6.24e-06	8.13e-05	CbGpPWpGaD
Pimozide—CALM3—Disease—KRAS—skin cancer	6.2e-06	8.08e-05	CbGpPWpGaD
Pimozide—DRD2—Signaling Pathways—NRAS—skin cancer	6.18e-06	8.05e-05	CbGpPWpGaD
Pimozide—DRD3—Signaling Pathways—TP53—skin cancer	6.18e-06	8.05e-05	CbGpPWpGaD
Pimozide—HTR2A—Signaling Pathways—NRAS—skin cancer	6.08e-06	7.92e-05	CbGpPWpGaD
Pimozide—HRH1—Signaling Pathways—NRAS—skin cancer	6.07e-06	7.9e-05	CbGpPWpGaD
Pimozide—HTR1A—Signaling Pathways—KRAS—skin cancer	6.06e-06	7.89e-05	CbGpPWpGaD
Pimozide—CALM2—Signaling by GPCR—HRAS—skin cancer	6.05e-06	7.88e-05	CbGpPWpGaD
Pimozide—CALM1—Signaling by GPCR—HRAS—skin cancer	6.05e-06	7.88e-05	CbGpPWpGaD
Pimozide—CYP3A4—Metabolism—ERCC2—skin cancer	6.04e-06	7.87e-05	CbGpPWpGaD
Pimozide—CYP2C19—Metabolism—PTGS2—skin cancer	6.03e-06	7.85e-05	CbGpPWpGaD
Pimozide—CALM2—Disease—KRAS—skin cancer	6e-06	7.82e-05	CbGpPWpGaD
Pimozide—CALM1—Disease—KRAS—skin cancer	6e-06	7.82e-05	CbGpPWpGaD
Pimozide—CALM3—Signaling by GPCR—IL6—skin cancer	5.98e-06	7.79e-05	CbGpPWpGaD
Pimozide—CHRM2—Signaling Pathways—NRAS—skin cancer	5.97e-06	7.78e-05	CbGpPWpGaD
Pimozide—OPRM1—Signaling Pathways—HRAS—skin cancer	5.97e-06	7.77e-05	CbGpPWpGaD
Pimozide—DRD3—Signaling Pathways—HRAS—skin cancer	5.91e-06	7.7e-05	CbGpPWpGaD
Pimozide—ABCB1—Metabolism—PTGS2—skin cancer	5.88e-06	7.66e-05	CbGpPWpGaD
Pimozide—CALM2—Signaling by GPCR—IL6—skin cancer	5.79e-06	7.54e-05	CbGpPWpGaD
Pimozide—CALM1—Signaling by GPCR—IL6—skin cancer	5.79e-06	7.54e-05	CbGpPWpGaD
Pimozide—CALM3—Immune System—HRAS—skin cancer	5.71e-06	7.44e-05	CbGpPWpGaD
Pimozide—OPRM1—Signaling Pathways—IL6—skin cancer	5.71e-06	7.44e-05	CbGpPWpGaD
Pimozide—DRD3—Signaling Pathways—IL6—skin cancer	5.66e-06	7.37e-05	CbGpPWpGaD
Pimozide—CYP2D6—Metabolism—PTGS2—skin cancer	5.54e-06	7.22e-05	CbGpPWpGaD
Pimozide—CALM2—Immune System—HRAS—skin cancer	5.53e-06	7.2e-05	CbGpPWpGaD
Pimozide—CALM1—Immune System—HRAS—skin cancer	5.53e-06	7.2e-05	CbGpPWpGaD
Pimozide—CALM3—Immune System—IL6—skin cancer	5.47e-06	7.12e-05	CbGpPWpGaD
Pimozide—HTR1A—Signaling Pathways—TP53—skin cancer	5.39e-06	7.01e-05	CbGpPWpGaD
Pimozide—DRD2—Signaling Pathways—KRAS—skin cancer	5.32e-06	6.93e-05	CbGpPWpGaD
Pimozide—CALM2—Immune System—IL6—skin cancer	5.29e-06	6.89e-05	CbGpPWpGaD
Pimozide—CALM1—Immune System—IL6—skin cancer	5.29e-06	6.89e-05	CbGpPWpGaD
Pimozide—CALM3—Disease—HRAS—skin cancer	5.27e-06	6.87e-05	CbGpPWpGaD
Pimozide—HTR2A—Signaling Pathways—KRAS—skin cancer	5.23e-06	6.82e-05	CbGpPWpGaD
Pimozide—HRH1—Signaling Pathways—KRAS—skin cancer	5.22e-06	6.8e-05	CbGpPWpGaD
Pimozide—HTR1A—Signaling Pathways—HRAS—skin cancer	5.15e-06	6.71e-05	CbGpPWpGaD
Pimozide—CHRM2—Signaling Pathways—KRAS—skin cancer	5.14e-06	6.69e-05	CbGpPWpGaD
Pimozide—CALM2—Disease—HRAS—skin cancer	5.1e-06	6.65e-05	CbGpPWpGaD
Pimozide—CALM1—Disease—HRAS—skin cancer	5.1e-06	6.65e-05	CbGpPWpGaD
Pimozide—CALM3—Signaling Pathways—NRAS—skin cancer	5.05e-06	6.58e-05	CbGpPWpGaD
Pimozide—CALM3—Disease—IL6—skin cancer	5.05e-06	6.58e-05	CbGpPWpGaD
Pimozide—HTR1A—Signaling Pathways—IL6—skin cancer	4.93e-06	6.42e-05	CbGpPWpGaD
Pimozide—CALM1—Signaling Pathways—NRAS—skin cancer	4.88e-06	6.36e-05	CbGpPWpGaD
Pimozide—CALM2—Signaling Pathways—NRAS—skin cancer	4.88e-06	6.36e-05	CbGpPWpGaD
Pimozide—CALM1—Disease—IL6—skin cancer	4.88e-06	6.36e-05	CbGpPWpGaD
Pimozide—CALM2—Disease—IL6—skin cancer	4.88e-06	6.36e-05	CbGpPWpGaD
Pimozide—DRD2—Signaling Pathways—TP53—skin cancer	4.73e-06	6.16e-05	CbGpPWpGaD
Pimozide—CYP1A2—Metabolism—PTGS2—skin cancer	4.69e-06	6.11e-05	CbGpPWpGaD
Pimozide—HTR2A—Signaling Pathways—TP53—skin cancer	4.65e-06	6.06e-05	CbGpPWpGaD
Pimozide—HRH1—Signaling Pathways—TP53—skin cancer	4.64e-06	6.05e-05	CbGpPWpGaD
Pimozide—CHRM2—Signaling Pathways—TP53—skin cancer	4.57e-06	5.95e-05	CbGpPWpGaD
Pimozide—DRD2—Signaling Pathways—HRAS—skin cancer	4.52e-06	5.89e-05	CbGpPWpGaD
Pimozide—HTR2A—Signaling Pathways—HRAS—skin cancer	4.45e-06	5.8e-05	CbGpPWpGaD
Pimozide—HRH1—Signaling Pathways—HRAS—skin cancer	4.44e-06	5.78e-05	CbGpPWpGaD
Pimozide—CHRM2—Signaling Pathways—HRAS—skin cancer	4.37e-06	5.69e-05	CbGpPWpGaD
Pimozide—CALM3—Signaling Pathways—KRAS—skin cancer	4.35e-06	5.66e-05	CbGpPWpGaD
Pimozide—DRD2—Signaling Pathways—IL6—skin cancer	4.33e-06	5.64e-05	CbGpPWpGaD
Pimozide—HTR2A—Signaling Pathways—IL6—skin cancer	4.26e-06	5.55e-05	CbGpPWpGaD
Pimozide—HRH1—Signaling Pathways—IL6—skin cancer	4.25e-06	5.53e-05	CbGpPWpGaD
Pimozide—CALM1—Signaling Pathways—KRAS—skin cancer	4.2e-06	5.47e-05	CbGpPWpGaD
Pimozide—CALM2—Signaling Pathways—KRAS—skin cancer	4.2e-06	5.47e-05	CbGpPWpGaD
Pimozide—CHRM2—Signaling Pathways—IL6—skin cancer	4.18e-06	5.45e-05	CbGpPWpGaD
Pimozide—CALM3—Signaling Pathways—TP53—skin cancer	3.86e-06	5.03e-05	CbGpPWpGaD
Pimozide—CALM2—Signaling Pathways—TP53—skin cancer	3.74e-06	4.87e-05	CbGpPWpGaD
Pimozide—CALM1—Signaling Pathways—TP53—skin cancer	3.74e-06	4.87e-05	CbGpPWpGaD
Pimozide—CALM3—Signaling Pathways—HRAS—skin cancer	3.69e-06	4.81e-05	CbGpPWpGaD
Pimozide—CYP3A4—Metabolism—PTGS2—skin cancer	3.62e-06	4.72e-05	CbGpPWpGaD
Pimozide—CALM2—Signaling Pathways—HRAS—skin cancer	3.57e-06	4.65e-05	CbGpPWpGaD
Pimozide—CALM1—Signaling Pathways—HRAS—skin cancer	3.57e-06	4.65e-05	CbGpPWpGaD
Pimozide—CALM3—Signaling Pathways—IL6—skin cancer	3.53e-06	4.6e-05	CbGpPWpGaD
Pimozide—CALM2—Signaling Pathways—IL6—skin cancer	3.42e-06	4.45e-05	CbGpPWpGaD
Pimozide—CALM1—Signaling Pathways—IL6—skin cancer	3.42e-06	4.45e-05	CbGpPWpGaD
